Boston MA, November 10, 2021 -- Today Darmiyan’s Chief Scientific Officer and Co-Founder Thomas Liebmann, PhD, presented to CTAD 2021 about the breakthrough work the company is doing to prognose Mild Cognitive Impairment (MCI) and detect Alzheimer’s disease early when treatments are feasible and there is hope to postpone or prevent dementia.
His online presentation “Early Detection of Alzheimer’s Disease with BrainSee, the FDA Breakthrough Software Medical Device” was among CTAD's innovative approaches and technologies shaping future clinical trials. BrainSee provides a 5 year prognosis of MCI and predicts which patients will convert to dementia.
The BrainSee output is a sensitive, patient-specific, and granular score between 0% and 100% that indicates the probability of conversion from MCI to Alzheimer’s dementia within 5 years. The lower the probability gets, as a result of any intervention (e.g. medications, lifestyle modifications, management of comorbidities, etc.), the lower the risk of progression to dementia within 5-years becomes. With objective and accurate brain monitoring, BrainSee can provide the best real-world evidence for the efficacy of any novel interventions in the Alzheimer’s space, paving the path to revolutionize how Alzheimer’s disease is viewed, detected and treated.
As a sensitive prognostic tool, BrainSee helps power future clinical trials by enhancing patient selection and excluding those patients who are less likely to progress to dementia and, therefore, less likely to benefit from the candidate drug.
Dr. Liebmann, a top microscopy expert, encouraged potential collaborators to contact him to learn more about the MCI conversion prediction modeling, noninvasive amyloid modeling and standardized diagnostic labelling that Darmiyan can provide to enhance pharmaceutical companies’ drug development.
"With the vision to democratize our solutions, we aim to empower all people to contribute to and benefit from the needed innovation in Alzheimer’s disease therapeutic development," reflected Dr. Liebmann.
“Darmiyan’s suite of novel products will be able to arm physicians and pharmaceutical companies with powerful information to develop new drugs and targeted treatment plans that can save lives, heartache, and billions of dollars,” Chief Medical and Technology Officer Kaveh Vejdani, MD, commented.
Darmiyan’s “ROC4” recorded session will be available throughout the hybrid Boston-based conference to press and registered participants via the portal. https://www.ctad-alzheimer.com/files/files/Program_CTAD2021_ONLINE.pdf”
Darmiyan Inc. has created the first virtual microscope of brain tissue that has been patented and earned FDA breakthrough status on its first medical device. Darmiyan was incorporated in September 2016 and backed by Y-Combinator (YC) in 2017. The Company’s awards include TEDMED Hive Innovator in 2018, CABHI Innovation Award in 2019 and UCSF Health Awards Finalist in 2021. CEO Padideh Kamali-Zare was listed in 2020 Fortune 40 Under 40 healthcare and in 2021 Healthcare Tech Report’s Top 25 Women in Biotechnology. Darmiyan's 2020 seed funding round was led by the global pharmaceutical giant Eisai with participation of YC and IT-Farm.
